A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells

by David H. Quach, Luis Becerra-Dominguez, Rayne H. Rouce, Cliona M. Rooney
Published 2019-07-01

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

by S Usmani, A Alonso, H Quach, Y Koh, A Guenther, CK Min, X Leleu, AO Abdallah, A Oriol, B Bessemer, M Garg, I Sandhu, K Weisel, E Ocio San Miguel, M Cavo, X Zhou, M Kaisermann, L Mis, D Williams, A Yeakey, G Ferron-Brady, D Figueroa, B Kremer, I Gupta, W Janowski
Published 2022-04-01